Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Status:
Completed
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating
the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib
placebo administered once per day compared to pimasertib administered twice per day plus
SAR245409 placebo administered once per day in participants with previously treated
unresectable low-grade serous ovarian or peritoneal carcinoma or serous borderline ovarian or
peritoneal tumors.